For an adult with major depressive disorder who has no history of seizures, no significant cardiac conduction problems, and is not taking other QT‑prolonging drugs, should I choose bupropion (Wellbutrin) or gepirone (Exxua)?

Bupropion (Wellbutrin) vs Gepirone (Exxua) for Major Depressive Disorder

Choose bupropion (Wellbutrin) over gepirone (Exxua) for this patient with major depressive disorder. Bupropion has decades of established efficacy, a well-characterized safety profile, and specific advantages including lower sexual dysfunction rates, while gepirone is a newly approved agent (2023) with limited real-world data and concerning QT prolongation requiring ECG monitoring 1, 2, 3.

Rationale Based on Guidelines

The American College of Physicians guidelines consistently recommend selecting second-generation antidepressants based on adverse effect profiles, cost, and patient preferences, noting that efficacy does not differ meaningfully between agents 1. The guidelines specifically highlight that bupropion is associated with lower rates of sexual adverse events compared to SSRIs like fluoxetine and sertraline 2—a quality-of-life advantage that matters significantly to patients.

Key Distinguishing Factors

Bupropion's advantages:

• No sexual dysfunction: Bupropion has the lowest rate of sexual side effects among antidepressants, a major quality-of-life consideration 2
• Established cardiovascular safety: Minimal cardiac conduction effects, rare orthostatic hypotension, and safe in patients with preexisting heart disease 4, 5
• No QT prolongation: Does not require ECG monitoring 6
• Decades of clinical experience: FDA-approved since the 1980s with extensive real-world data 7
• Additional benefits: May help with smoking cessation and does not cause weight gain 6

Gepirone's limitations:

• QT prolongation risk: Requires baseline ECG, correction of electrolyte abnormalities, and periodic ECG monitoring during treatment 3
• Contraindicated if baseline QTc >450 msec or in congenital long QT syndrome 3
• Limited clinical experience: Only FDA-approved in 2023 with fewer published studies 8
• Smaller effect sizes: Historical studies showed more failed trials and smaller efficacy compared to other antidepressants 9
• Common side effects: Dizziness (45%), nausea (36%), headache (24%) 10

Clinical Decision Algorithm

Step 1: Assess seizure risk

• History of seizures or epilepsy? → Avoid bupropion 6
• Eating disorder (anorexia/bulimia)? → Avoid bupropion 6
• If neither present → Bupropion is safe (seizure risk 0.1-0.4% at ≤450 mg/day, comparable to other antidepressants) 7

Step 2: Assess cardiac considerations

• Your patient has no significant cardiac conduction problems → Bupropion preferred
• If QT prolongation concerns existed → Would need ECG monitoring with gepirone anyway 3

Step 3: Consider quality-of-life factors

• Sexual function important? → Bupropion strongly preferred 2
• Concurrent smoking cessation needed? → Bupropion preferred 6
• Want to avoid weight gain? → Bupropion preferred 6

Practical Prescribing

Bupropion dosing:

• Start 150 mg once daily for 3 days
• Increase to 150 mg twice daily (or 300 mg XL once daily)
• Maximum 450 mg/day in divided doses 6
• Take with food; avoid late-day dosing to minimize insomnia 6

Monitoring:

• Assess response at 1-2 weeks 1
• Modify treatment if inadequate response by 6-8 weeks 1
• Monitor blood pressure (can cause mild increases) 6
• Watch for activation/agitation in first 1-2 months 1

Common Pitfalls to Avoid

1. Don't exceed 450 mg/day of bupropion or give >150 mg as a single dose—this increases seizure risk 6, 7
2. Don't combine with MAOIs—requires 14-day washout period for both agents 6, 3
3. Don't abruptly stop alcohol/sedatives when starting bupropion—increases seizure risk 6
4. Don't choose gepirone if patient cannot comply with ECG monitoring requirements 3

Evidence Quality Considerations

The guidelines recommending bupropion are based on moderate-quality evidence from multiple large trials and decades of clinical use 1, 2. Gepirone's approval was based on phase 3 trials showing efficacy, but with significantly less real-world experience 8, 10. One 2008 study showed gepirone efficacy by week 4, but with 45% experiencing dizziness 10. A 2025 review noted gepirone had "more failed/negative studies and smaller effect size" compared to other antidepressants 9.

The cardiovascular safety profile of bupropion is particularly well-established: studies in over 700 patients, including those with preexisting heart disease, showed no adverse effects on heart rate, blood pressure, or cardiac conduction 4, 5. This contrasts sharply with gepirone's requirement for ECG monitoring due to QT prolongation 3.

Given equal efficacy between second-generation antidepressants per guidelines 1, 11, the decision hinges on safety profile and quality-of-life considerations—both favoring bupropion for this patient without seizure history or cardiac conduction problems.